ACVR1C抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07758(ACVR1C Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07758(ACVR1C Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

The ACVR1C antibody targets activin receptor-like kinase 7 (ALK7), a type I transmembrane serine/threonine kinase receptor in the TGF-β superfamily. ACVR1C/ALK7 binds activins, nodal, and growth differentiation factors (GDFs), mediating SMAD-dependent signaling pathways critical for cellular processes like differentiation, apoptosis, and metabolism. It is expressed in tissues including adipose, pancreas, and the nervous system, and has been implicated in metabolic regulation, cancer, and fibrosis.

ACVR1C antibodies are valuable tools for research, enabling detection of receptor expression, localization, and activation in disease models. In cancer, ACVR1C overexpression or mutation may drive tumor progression, making it a potential therapeutic target. Antibodies blocking ACVR1C activity are explored for inhibiting oncogenic signaling. Conversely, in metabolic disorders, modulating ACVR1C signaling could influence insulin sensitivity or lipolysis.

Commercial ACVR1C antibodies are typically monoclonal or polyclonal, validated for applications like Western blot, immunohistochemistry, or flow cytometry. Challenges include ensuring specificity due to homology with other TGF-β receptors. Recent studies also investigate ACVR1C's role in fibrosis and immune regulation, expanding its therapeutic relevance. Developing therapeutic antibodies or small-molecule inhibitors against ACVR1C remains an active area, with ongoing preclinical studies assessing efficacy and safety in related pathologies.